LP39 : Implications of baseline HCVRNA level and intrapatient viral load variability on OBV/PTV/R + DSV 12-week treatment outcomes von Brown, R.S, Puoti, M, Cooper, C, Wyles, D.L, Sepe, T.E, Nahass, R.G, King, M, Coakley, E, McGovern, B.H, Feld, J.J

Volltext

Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study von Poordad, F, Bennett, M, Sepe, T.E, Cohen, E, Reindollar, R.W, Everson, G, Phillips, R.W, Siddique, A, Sullivan, J.G, Box, T.D, Fu, B, Pilot-Matias, T, Abunimeh, M, Cohen, D.E, Younes, Z

Volltext

SAT-156 - Ombitasvir/Paritaprevir/R, Dasabuvir, and Sofosbuvir Treatment of Patients with HCV Genotype-Infection who Failed a Prior Course of DAA Therapy: The Quartz-I Study von Poordad, F., Bennett, M., Sepe, T.E., Cohen, E., Reindollar, R.W., Everson, G., Phillips, R.W., Siddique, A., Sullivan, J.G., Box, T.D., Fu, B., Pilot-Matias, T., Abunimeh, M., Cohen, D.E., Younes, Z.

Volltext